Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-932 as an Adjunct to Antidepressant Therapies in Generalized Anxiety Disorder
NCT06846320Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ABBV-932 in generalized anxiety disorder (GAD), sponsored by AbbVie Inc.. Started Apr 2025; status: recruiting.
02
Drugs
ABBV-932
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06846320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846320.